In a randomized controlled trial terminated early owing to lower than expected event rates,
neither acetylsalicylic acid (ASA) nor apixaban (at prophylactic or therapeutic doses) …

The recent observational study reported by Soudet et al. 1 provides insights into the
incidence of venous thromboembolism (VTE) among patients afflicted by coronavirus …

Since the beginning of the pandemic caused by the novel SARS-CoV-2 the coronavirus
disease-2019 (COVID-19) has emerged as a highly prothrombotic viral disease leading to …

Abstract Background Coronavirus disease (COVID-19) is a global health emergency, with
well over six hundred million infections and over six million deaths to date. Besides other …

Importance Acutely ill inpatients with COVID-19 typically receive antithrombotic therapy,
although the risks and benefits of this intervention among outpatients with COVID-19 have …

Early in the COVID-19 pandemic, infection with SARS-CoV-2 was noted to be associated
with a coagulopathy [1] and high rates of VTE observed in ICU patients, leading many to …

COVID-19 is associated with an inflammatory vascular and hypercoagulable response
leading to increased risk of venous and arterial thromboembolism. Microvascular pulmonary …

Background: On March 11, 2020, World Health Organization announced that severe acute
respiratory syndrome coronavirus 2 caused COVID-19 was a global pandemic. COVID-19 is …

COVID-19, the infectious disease caused by the SARS-CoV-2 virus, has been associated
with an inflammatory and hypercoagulable state characterized by increases in levels of D …

Purpose: Heparin-based regimens are recommended for anticoagulation in hospitalized
patients with COVID-19 though a study reported similar mortality with apixaban in critically ill …